NXL · Nexalin Technology, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated these conditions and concluded that the Company does not currently have sufficient cash and cash equivalents to fund its anticipated operating requirements for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Accordingly, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-12-19 | White Mark |
Director, CEO |
Award↑
|
Stock Option (right to buy)*
|
1,000,000 |
| 2025-12-19 | Hu Ben |
Director |
Award↑
|
Stock Option (right to buy)*
|
100,000 |
| 2025-12-19 | Van Fleet Justin |
CFO |
Award↑
|
Stock Option (right to buy)*
|
100,000 |
| 2025-12-19 | Shelton Carolyn Hamby |
Sr. VP - Quality - Regulatory |
Award↑
|
Stock Option (right to buy)*
|
100,000 |
| 2025-12-19 | Kazden Alan |
Director |
Award↑
|
Stock Option (right to buy)*
|
100,000 |
| 2025-12-19 | Owens David |
Director, Chief Medical Officer |
Award↑
|
Stock Option (right to buy)*
|
1,000,000 |
| 2025-09-29 | Hu Ben |
Director |
Award↑
Filing footnotes — Common stock (Direct)
Includes 372,929 shares held by Mr. Hu, 3,582 shares held jointly by Mr. Hu and Amy Lun Hu, his spouse, and 584 shares held jointly by Mr. Hu and David D. Hu, his son. |
Common stock
|
36,459 |
| 2025-09-29 | Owens David |
Director, Chief Medical Officer |
Award↑
|
Common stock
|
36,459 |
| 2025-09-29 | OSSER LEONARD |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Includes shares that Reporting Person owns with spouse Leonard Osser and for which Reporting Person has shared voting and dispositive power with spouse. Form 4 filed as joint ownership filing |
Common Stock
|
83,333 |
| 2025-09-29 | Kazden Alan |
Director |
Award↑
Filing footnotes — Common stock (Indirect)
Reporting Person has dispositive and voting control of the shares. |
Common stock
(I)
|
36,459 |
| 2025-09-12 | Owens David |
Director, Chief Medical Officer |
Award↑
|
Stock Option (right to buy)
|
100,000 |
| 2025-09-12 | Shelton Carolyn Hamby |
Sr. VP - Quality - Regulatory |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The reporting person was granted an option to purchase 20,000 shares of common stock. The option vests in three equal annual installments for each of the annual periods ending December 27, 2025, 2026 and 2027. |
Stock Option (right to buy)
|
20,000 |
| 2025-09-12 | Owens David |
Director, Chief Medical Officer |
Award↑
|
Stock Option (right to buy)
|
203,125 |
| 2025-09-10 | Elson Marilyn |
10% Owner |
Sell↓
|
Common Stock Warrants
|
23,150 |
| 2025-07-17 | Elson Marilyn |
10% Owner |
Award↑
|
Stock Option (right to buy)
|
30,000 |
| 2025-07-17 | Elson Marilyn |
10% Owner |
Award↑
|
Stock Option (right to buy)
|
30,000 |
| 2025-07-17 | Elson Marilyn |
10% Owner |
Award↑
|
Stock Option (right to buy)
|
30,000 |
| 2025-07-17 | Elson Marilyn |
10% Owner |
Award↑
|
Stock Option (right to buy)
|
30,000 |
| 2025-07-17 | Elson Marilyn |
10% Owner |
Award↑
|
Stock Option (right to buy)
|
150,000 |
| 2025-07-17 | Elson Marilyn |
10% Owner |
Award↑
|
Stock Option (right to buy)
|
30,000 |
| 2025-03-12 | Shelton Carolyn Hamby |
Sr. VP - Quality - Regulatory |
Buy↑
Filing footnotes — Common Stock (Indirect)
Includes 24,000 shares owned directly by Reporting Person. |
Common Stock
(I)
|
6,000 |
| 2025-02-26 | Owens David |
Director, Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending June 30, 2024, 2025 and 2026. The performance criteria for the period ending June 30, 2024 were met, resulting in the vesting of options to purchase 218,121 shares. |
Stock Option (right to buy)
|
654,363 |
| 2025-02-26 | Owens David |
Director, Chief Medical Officer |
Award↑
|
Stock Option (right to buy)
|
125,000 |
| 2025-02-26 | Owens David |
Director, Chief Medical Officer |
Award↑
|
Stock Option (right to buy)
|
139,821 |
| 2025-02-26 | White Mark |
Director, CEO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending June 30, 2024, 2025 and 2026. The performance criteria for the period ending June 30, 2024 were met, resulting in the vesting of options to purchase 313,199 shares. |
Stock Option (right to buy)
|
939,597 |
| 2025-02-26 | White Mark |
Director, CEO |
Award↑
|
Stock Option (right to buy)
|
447,427 |
| 2025-02-04 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,000 |
| 2025-02-04 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,000 |
| 2025-01-28 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,500 |
| 2025-01-23 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,000 |
| 2025-01-13 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
2,000 |
| 2024-12-20 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,000 |
| 2024-11-07 | Owens David |
Director, Chief Medical Officer |
Award↑
|
Stock Option (right to buy)
|
262,500 |
| 2024-11-07 | Shelton Carolyn Hamby |
Sr. VP - Quality - Regulatory |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The reporting person was granted an option to purchase 90,620 shares of common stock. The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending September 16, 2025, 2026 and 2027. |
Stock Option (right to buy)
|
90,620 |
| 2024-11-02 | Kazden Alan |
Director |
Buy↑
|
Stock Option (right to buy)
|
262,500 |
| 2024-10-28 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
500 |
| 2024-10-14 | Shelton Carolyn Hamby |
Sr. VP - Quality - Regulatory |
Buy↑
Filing footnotes — Common stock (Direct)
Represents shares purchased after appointment as Senior Vice President, Quality, Regulatory and Clinical Affairs. |
Common stock
|
24,000 |
| 2024-09-30 | Bernhard Leslie |
Director |
Award↑
|
Common stock
|
49,838 |
| 2024-09-30 | Elson Marilyn |
10% Owner |
Award↑
|
Common Stock
|
700,000 |
| 2024-09-30 | Hu Ben |
Director |
Award↑
Filing footnotes — Common stock (Direct)
Includes 336,470 shares held by Mr. Hu, 3,582 shares held jointly by Mr. Hu and Amy Lun Hu, his spouse, and 584 shares held jointly by Mr. Hu and David D. Hu, his son |
Common stock
|
175,000 |
| 2024-08-13 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,000 |
| 2024-06-28 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,000 |
| 2024-06-18 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,619 |
| 2024-06-10 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
1,000 |
| 2024-06-10 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock
|
2,000 |
| 2022-09-28 | Elson Marilyn |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
Includes shares that Reporting Person owns with spouse Leonard Osser and for which Reporting Person has shared voting and dispositive power with spouse. Form 4 filed as joint ownership filing |
Common Stock
(I)
|
9,500 |
| 2022-09-28 | Elson Marilyn |
10% Owner |
Buy↑
|
Common stock warrants
|
36,000 |
| 2022-09-16 | Elson Marilyn |
10% Owner |
Buy↑
|
Common stock warrants
|
100,000 |
| 2022-09-16 | Owens David |
Director, Chief Medical Officer |
Buy↑
|
Common stock warrants
|
2,500 |
| 2022-09-16 | Kazden Alan |
Director |
Buy↑
|
Common stock warrants
|
2,500 |